EUVIMEDEUVIMED entdecken
Klinische Studie (Phase IV)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access

Can We Predict Who Will Experience Adverse Events While Using Smoking Cessation Pharmacotherapy? A Secondary Analysis of the EAGLES Clinical Trial

Bethany J Wolf iD, Kevin M Gray, Jennifer R Dahne iD, Daniel Hashemi, Rachel L Tomko iD

Nicotine and Tobacco Research · 2025

DOI: 10.1093/ntr/ntae290 ↗

Kurz gefasst

Klinische Studie (Phase IV) in der Zeitschrift Nicotine and Tobacco Research, 2025. Verfasst von Bethany J Wolf und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC, USA. Hauptthemen laut MEDLINE: Smoking Cessation, Smoking Cessation Agents, Tobacco Use Cessation Devices. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Concerns about potential side effects remain a barrier to uptake of Food and Drug Administration-approved smoking cessation pharmacotherapy (ie, varenicline, bupropion, nicotine replacement therapy [NRT]). However, use of pharmacotherapy can double the odds of successful quitting. Knowledge of an individual’s likelihood of side effects while taking smoking cessation pharmacotherapy could influence treatment planning discussions and monitoring.

Methods

We conducted a secondary, post hoc analysis to predict an individual’s likelihood of adverse events (AEs) using the Evaluating Adverse Events in a Global Smoking Cessation Study data from 4209 adults in the United States who smoked. Participants were randomized to receive 12 weeks of treatment with varenicline, bupropion, NRT patch, or placebo. Our models predicted the likelihood of moderate to severe psychiatric and nonpsychiatric AEs during treatment.

Results

Using pretreatment demographic and clinical data, multivariable logistic regression models yielded acceptable areas under the receiver operating characteristic curve for an individual’s likelihood of moderate to severe (1) psychiatric AEs for bupropion and NRT and (2) nonpsychiatric AEs for varenicline and bupropion. Once we adjusted for demographic and baseline characteristics, medication was not associated with psychiatric AEs. Varenicline differed from placebo with regards to nonpsychiatric AEs.

Conclusions

It is possible to predict person-specific likelihood of moderate to severe psychiatric and nonpsychiatric AEs during smoking cessation treatment, though the probability of psychiatric AEs did not differ by medication. Future work should consider factors related to implementation in clinical settings, including determining whether lower burden assessment protocols can be equally accurate for AE prediction.

Implications

Using data from a large dataset people who smoke in the United States, it is possible to predict an individual’s likelihood of psychiatric and nonpsychiatric AEs during smoking cessation treatment prior to initiating treatment. These predictive models provide a starting point for future work addressing how best to modify and integrate such clinical decision support algorithms into treatment for smoking cessation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Smoking CessationSmoking Cessation AgentsTobacco Use Cessation DevicesAdultFemaleHumansMaleMiddle AgedBupropionUnited StatesVarenicline

Substanzen

BupropionSmoking Cessation AgentsVarenicline

Autor:innen und Institutionen

  • Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC, USA.
  • Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, USA.
  • Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA.
  • Department of Psychiatry, Harvard Medical School, Boston, MA, USA.

ORCID-Profile: Bethany J Wolf, Jennifer R Dahne, Rachel L Tomko

Förderung

  • NCI NIH HHS
  • National Cancer Institute

Zitieren

APA

Wolf, B. J., Gray, K. M., Dahne, J. R., Hashemi, D., & Tomko, R. L. (2025). Can We Predict Who Will Experience Adverse Events While Using Smoking Cessation Pharmacotherapy? A Secondary Analysis of the EAGLES Clinical Trial. Nicotine and Tobacco Research. https://doi.org/10.1093/ntr/ntae290

Vancouver

Wolf BJ, Gray KM, Dahne JR, Hashemi D, Tomko RL. Can We Predict Who Will Experience Adverse Events While Using Smoking Cessation Pharmacotherapy? A Secondary Analysis of the EAGLES Clinical Trial. Nicotine and Tobacco Research. 2025. doi:10.1093/ntr/ntae290

BibTeX
@article{Wolf2025,
  author = {Wolf, Bethany J and Gray, Kevin M and Dahne, Jennifer R and Hashemi, Daniel and Tomko, Rachel L},
  title = {Can We Predict Who Will Experience Adverse Events While Using Smoking Cessation Pharmacotherapy? A Secondary Analysis of the EAGLES Clinical Trial},
  journal = {Nicotine and Tobacco Research},
  year = {2025},
  doi = {10.1093/ntr/ntae290}
}
Kostenlos starten →